Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
Janssen Research & Development, LLC
Natasha B Leighl; Hiroaki Akamatsu; Sun Min Lim; Ying Cheng; Anna R Minchom; Melina E Marmarelis; Rachel E Sanborn; James Chih-Hsin Yang; Baogang Liu; Thomas John; Bartomeu Massutí; Alexander I Spira; Se-Hoon Lee; Jialei Wang; Juan Li; Caigang Liu; Silvia Novello; Masashi Kondo; Motohiro Tamiya; Ernesto Korbenfeld; Mor Moskovitz; Ji-Youn Han; Mariam Alexander; Rohit Joshi; Enriqueta Felip; Pei Jye Voon; Pongwut Danchaivijitr; Ping-Chih Hsu; Felipe José Silva Melo Cruz; Thomas Wehler; Laurent Greillier; Encarnação Teixeira; Danny Nguyen; Joshua K Sabari; Angel Qin; Dariusz Kowalski; Mehmet Ali Nahit Şendur; John Xie; Debopriya Ghosh; Ali Alhadab; Nahor Haddish-Berhane; Pamela L Clemens; Patricia Lorenzini; Remy B Verheijen; Mohamed Gamil; Joshua M Bauml; Mahadi Baig; Antonio Passaro; PALOMA-3 Investigators